Structure-activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 20, 2003, Pages 3593-3596

  Elliott, Richard L ^a   Oliver, Robert M ^a   LaFlamme, Janet A ^a   Gillaspy, Melissa L ^a   Hammond, Marlys ^a   Hank, Richard F ^a   Maurer, Tristan S ^a   Baker, Demetria L ^a   DaSilva Jardine, Paul A ^a   Stevenson, Ralph W ^a   Mack, Christine M ^b   Cassella, James V ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b NEUROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLE DERIVATIVE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ELECTRON; FEEDING; IN VITRO STUDY; LOCOMOTION; MALE; NONHUMAN; RAT; RODENT; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

RODENTIA;

EID: 10744229281     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00747-9     Document Type: Article

References (13)

1. (a) Wyss P., Stricker-Krongrad A., Brunner L., Miller J., Crossthwaite A., Whitebread S., Criscione L. Reg. Peptides. 75-76:1998;363
2. (b) Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branshek T.A., Weinshank R.L. Nature (London). 382:1996;168.
3. Widdowson P.S. Brain Res. 758:1997;17.
4. (a) Schaffhauser A.O., Stricker-Krongrad A., Brunner L., Cumin F., Gerald C., Whitebread S., Criscione L., Hofbauer K.G. Diabetes. 46:1997;1792
5. (b) Tang-Christensen M., Kristensen P., Stidsen C.E., Brand C.L., Larsen P.J. J. Endocrin. 159:1998;307
6. (c) Flynn M.C., Turrin N.P., Plata-Salaman C.R., Ffrench-Mullen J.M. Physiol. Behav. 66:1999;881.
7. The in vitro binding and functional assays were performed as described in patent WO9901128.
8. Very recently a series of 2,4-diarylimidazoles was reported on in which compound 9 was observed to cause weight loss in diet-induced obese rats when dosed over a 28-day period at 10 mg/kg/day po: Boyle, C. D.; Lankin, C; Chackalamannil, S.; Manna, M.; Stamford, A.; Mullins, D.; Guzzi, M.; Salisbury, B.; Hwa, J.; Ghibaudi, L.; Witten, M.; Gao, J.; Van Heek, M.; France, C.; Cook, J.; Bryant, M. 2,4-Diarylimidazoles as neuropeptide Y5 receptor antagonists. 224th ACS National Meeting (Boston, Aug. 18-22, 2002; Poster #335).
9. Kalvass J.C., Maurer T.S. Biopharm. Drug. Dispos. 23:2002;327.
10. Elliott R.L., Oliver R.M., Hammond M., Patterson T.A., She L., Hargrove D.M., Martin K.A., Maurer T.S., Kalvass J.C., Morgan B.P., DaSilva-Jardine P.A., Stevenson R.W., Mack C.M., Cassella J.V. J. Med. Chem. 46:2003;670.
11. Kanatani A., Ishihara A., Iwaasa H., Nakamura K., Okamoto O., Hidaka M., Ito J., Fukuroda T., MacNeil D.J., Van der Ploeg L.H.T., Ishii Y., Okabe T., Fukami T., Ihara M. Biochem. Biophys. Res. Commun. 272:2000;169.
12. Turnbull A.V., Ellershaw L., Masters D.J., Birtles S., Boyer S., Carroll D., Clarkson P., Loxham S.J.G., McAulay P., Teague J.L., Foote K.M., Pease J.E., Block M.H. Diabetes. 51:2002;2441.
13. Block M.H., Boyer S., Brailsford W., Brittain D.R., Carroll D., Chapman S., Clarke D.S., Donald C.S., Foote K.M., Godfrey L., Ladner A., Marsham P.R., Masters D.J., Mee C.D., O'Donovan M.R., Pease J.E., Pickup A.G., Rayner J.W., Roberts A., Schofield P., Suleman A., Turnbull A.V. J. Med. Chem. 45:2002;3509.